USPTO serial 85482864
BETTER MAB
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- EVANKO, PATRICIA MALESARDI
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with BETTER MAB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
David L. May
DAVID L. MAY NIXON PEABODY, LLP401 9TH ST N.W. STE 900WASHINGTON, DC 20004UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals, biochemicals and reagents for use in industry and science; Chemicals for use in biochemical and chemical industry; chemicals for use in agriculture; chemicals for use in biotechnological product development; chemicals for use in biotechnological manufacturing processes; chemical preparations for scientific purposes; chemical reagents for non-medical purposes; chemicals, biochemicals and reagents, namely, proteins for regulating, modifying or restricting cellular activity or gene expression, ligands, genetic vectors, genetic hosts, genetic biochemicals, genetic bioengineering reagents and proteins for use in modifying and regulating cellular functions in transgenic plants, fungi and animals, and in cells of plants, fungi and animals; antibodies for scientific and research use; antibodies for regulating, modifying or regulating cellular functions in plants, fungi and animals, and in cells of plants, fungi and animals; kits consisting primarily of proteins for regulating, modifying or restricting cellular activity or gene expression; Research reagents for pharmaceutical discovery or disease research, drug discovery or drug development; Chemical inducers of gene expression in plants, mammals, fungi and bacteria for industrial and agricultural applications; all of the foregoing featuring, including or involving monoclonal antibodies or portions thereof | ACTIVE | — |
| 005 | Chemical preparations for medical and veterinary purposes, namely, chemical preparations for regulating, modifying, or restricting cellular activity or gene expression for purposes of treating diseases and genetic disorders; chemical preparations for antibody therapy, for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for therapeutic analysis; biochemical preparations for medical and veterinary purposes, namely, biochemical preparations for antibody therapy, for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for antibody therapy analysis; Pharmaceutical preparations for modifying or regulating one or more cellular functions of mammals, fungi, plants, and bacteria and transgenic mammals, fungi, plants, and bacteria; transgenic plants, fungi and bacteria for medical and veterinary purposes; antibodies for use in disease testing; all of the foregoing featuring, including or involving monoclonal antibodies or portions thereof | ACTIVE | — |
| 040 | Custom manufacturing and custom synthesis of antibodies and genetically engineered DNA expressing antibodies, biological organisms, cells, viruses, pathogens and special purpose cells to the specifications of others for scientific, research, medical, veterinary and laboratory use; all of the foregoing featuring, including or involving monoclonal antibodies or portions thereof | ACTIVE | — |
| 042 | Development of new technology for others in the field of genetics, therapeutics and biotechnology; Development of products being antibodies and genetic therapies expressing antibodies to regulate, modulate, treat, prevent, and characterize disease states; Development of tools in the nature of software and biotechnological processes to regulate, modulate, and characterize disease states; Research and development services for others in the fields of biotechnology and antibody technology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells expressing antibodies for scientific, research, medical, veterinary and laboratory use; Scientific research and product development services for others in the pharmaceutical, biotechnology, biosensors, bioelectronics, medical and agriculture fields; Antibody technology and gene therapy services for others for product development and scientific research purposes, namely, antibody production, genetically engineering DNA expressing antibodies, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical, veterinary and laboratory use; all of the foregoing featuring, including or involving monoclonal antibodies or portions thereof | ACTIVE | — |
| 044 | Medical services; Medical services, namely, antibody and gene therapy services; all of the foregoing featuring, including or involving monoclonal antibodies or portions thereof | ACTIVE | — |
| 045 | Technology transfer services, namely, licensing and transfer of intellectual property; all of the foregoing featuring, including or involving monoclonal antibodies or portions thereof | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Intrexon Corporation
- Other trademarks owned by Intrexon Corporation
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named BETTER MAB
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 1, 2016 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 1, 2016 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 9, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 8, 2015 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jun 23, 2015 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jun 23, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 16, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 15, 2014 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Dec 11, 2014 | EXT4 | SOU EXTENSION 4 FILED | — |
| Dec 11, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 3, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 2, 2014 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 28, 2014 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 28, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 31, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 30, 2014 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jan 24, 2014 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 24, 2014 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 4, 2013 | EXT2 | SOU EXTENSION 2 FILED | — |
| Dec 4, 2013 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 20, 2013 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 18, 2013 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 18, 2013 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 18, 2013 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 25, 2012 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 30, 2012 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 30, 2012 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 10, 2012 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 21, 2012 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 20, 2012 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 20, 2012 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 20, 2012 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 20, 2012 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 20, 2012 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 7, 2012 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 7, 2012 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 7, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 4, 2012 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Aug 26, 2012 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Aug 10, 2012 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 10, 2012 | ALIE | ASSIGNED TO LIE | — |
| Jul 27, 2012 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 27, 2012 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 27, 2012 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2012 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2012 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 20, 2012 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 19, 2012 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 19, 2012 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 14, 2012 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 14, 2012 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 14, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 12, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 5, 2011 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 2, 2011 | NWAP | NEW APPLICATION ENTERED | — |